

Antibe Therapeutics, Inc.

09:36 13 Jan 2020

Antibe Therapeutics bolsters executive team in preparation for ATB-346 commercialization

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) took another step towards commercializing its lead drug ATB-346 with the hiring of a new executive team member.

Seasoned pharmaceutical executive Dr Rami Batal is joining the Toronto-based company as its new senior vice president, commercial strategy.

With experience in pharmaceutical development and commercialization of pain drugs globally, Batal helped guide in-licensing on behalf of major pharma companies.

READ: Antibe Therapeutics running largest number of sites for any clinical trial in Canada in ATB-346 study

Batal is tasked with leveraging Antibe's recent business development initiatives, which include its recent health economics study and the ongoing comprehensive market opportunity assessment and payor study.

A key aspect of the role involves providing partners with a robust commercial strategy package, including an in-depth framework on positioning, launch-planning and reimbursement, according to Antibe.

"This new role will help us maximize the value of ATB-346 as we ramp up partnering discussions for the larger markets," said Antibe's CEO Dan Legault in a statement Monday.

"Rami's deep experience in commercialization of analgesics will enable us to fully capture and communicate the drug's commercial potential to our partners. We are delighted to welcome him to our growing team."

ATB-346 targets acute and chronic pain associated with osteoarthritis. Currently, in Phase 2 trials, the drug is a naproxen-derivative that has been shown to deliver pain relief with significantly less gastrointestinal damage than typical NSAID usage.

Antibe also announced that it promoted Scott Curtis to the role of executive vice president, where he will be responsible for coordinating corporate activities as the company's business development initiatives take flight this year.

Contact Angela at angela@proactiveinvestors.com


Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 0.63

Market Cap: \$177.21 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: ATE

Listing: TSX-V

52 week	High	Low
	0.68	0.26

Sector: Pharma & Biotech

Website: antibether.com

Company Synopsis:

Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a \$20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention.

action@proactiveinvestors.com

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics, Inc. named herein, including the promotion by the Company of Antibe Therapeutics, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).